Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
24 hedge funds and large institutions have $15.1M invested in Telesis Bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less funds holding
Funds holding: 32 → 24 (-8)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
28% less capital invested
Capital invested by funds: $20.9M → $15.1M (-$5.81M)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $24K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$311K |
| 2 |
VF
Virtu Financial
New York
|
+$35.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.3K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$7.09K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$109K |
| 2 |
Renaissance Technologies
New York
|
-$96.8K |
| 3 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
-$85K |
| 4 |
D.E. Shaw & Co
New York
|
-$66K |
| 5 |
E
Ergoteles
New York
|
-$63K |
TBIO Hedge Fund Activity: Q4 2022 in Review
24 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q4 2022, worth a combined $15.1M — down 28% from $20.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TBIO and 2 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Penn Capital Management, adding an estimated $311K. The largest seller was BlackRock, cutting an estimated $109K.
- 24 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q4 2022, down from 32 in Q3 2022.
- Funds reported $15.1M of Telesis Bio, Inc. Common Stock stock for Q4 2022, down 28% quarter-over-quarter.
- 2 funds opened new Telesis Bio, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of -8 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q4 2022 was Penn Capital Management, an estimated $311K added.
- The largest Telesis Bio, Inc. Common Stock seller in Q4 2022 was BlackRock, an estimated $109K sold.
Based on aggregated 13F filings for Q4 2022.